{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "27376845",
  "DateCompleted": {
    "Year": "2017",
    "Month": "09",
    "Day": "26"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "03",
    "Day": "16"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2016",
        "Month": "07",
        "Day": "01"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1159/000447630"
    ],
    "Journal": {
      "ISSN": "1421-9913",
      "JournalIssue": {
        "Volume": "76",
        "Issue": "1-2",
        "PubDate": {
          "Year": "2016"
        }
      },
      "Title": "European neurology",
      "ISOAbbreviation": "Eur Neurol"
    },
    "ArticleTitle": "Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-\u03b2 to Glatiramer Acetate in Clinical Practice.",
    "Pagination": {
      "StartPage": "40",
      "EndPage": "47",
      "MedlinePgn": "40-7"
    },
    "Abstract": {
      "AbstractText": [
        "The immunomodulatory effect of glatiramer acetate may help in reducing multiple sclerosis (MS)-related fatigue; however, evidence to prove this notion especially after switching from another immunomodulatory therapy is limited. We assessed the 6-month effect of glatiramer acetate on MS-related fatigue in patients switching from interferon-\u03b2 (IFN-\u03b2) in clinical practice.",
        "This was an observational study including 54 patients with relapsing-remitting MS that showed moderate/severe fatigue primarily caused by MS before switching from IFN-\u03b2 to glatiramer acetate and received glatiramer acetate for \u22656 months in daily practice. Study data were retrospectively collected through chart review at treatment switch and over the following 6 months on glatiramer acetate.",
        "Over the 6-month administration of glatiramer acetate, scores on the Modified Fatigue Impact Scale decreased: overall (p < 0.001), physical scale (p < 0.001), cognitive scale (p < 0.001), and psychosocial scale (p < 0.001). The Work Productivity and Activity Impairment Questionnaire showed improvements in work (p = 0.009) and other daily activity impairment (p < 0.001). Health-related quality of life as per the Multiple Sclerosis Impact Scale also improved: physical score (p < 0.001) and psychological score (p < 0.001).",
        "Patients with moderate/severe fatigue switching from IFN-\u03b2 to glatiramer acetate may benefit from fatigue improvements that contribute to reduce their work/activity impairment and improve their quality of life."
      ],
      "CopyrightInformation": "\u00a9 2016 S. Karger AG, Basel."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Neurology, Multiple Sclerosis Unit, Hospital Clx00ED;nico Universitario x2018;Virgen de la Arrixaca', Murcia, Spain."
          }
        ],
        "LastName": "Meca-Lallana",
        "ForeName": "Jos\u00e9",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Hern\u00e1ndez",
        "ForeName": "Luis",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Caminero",
        "ForeName": "Ana Bel\u00e9n",
        "Initials": "AB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gir\u00f3n",
        "ForeName": "Juan Miguel",
        "Initials": "JM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cano-Orgaz",
        "ForeName": "Antonio",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Carcel\u00e9n-Gadea",
        "ForeName": "Mar\u00eda",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mu\u00f1oz",
        "ForeName": "Delicias",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Dur\u00e1n-Ferreras",
        "ForeName": "Eduardo",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mart\u00edn-Hern\u00e1ndez",
        "ForeName": "Javier",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "S\u00e1nchez-de la Rosa",
        "ForeName": "Rainel",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "CollectiveName": "FATIGA Study Group"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Eur Neurol",
    "NlmUniqueID": "0150760",
    "ISSNLinking": "0014-3022"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunosuppressive Agents"
    },
    {
      "RegistryNumber": "5M691HL4BO",
      "NameOfSubstance": "Glatiramer Acetate"
    },
    {
      "RegistryNumber": "77238-31-4",
      "NameOfSubstance": "Interferon-beta"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Substitution"
    },
    {
      "QualifierName": [
        "drug therapy",
        "etiology"
      ],
      "DescriptorName": "Fatigue"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "therapeutic use"
      ],
      "DescriptorName": "Glatiramer Acetate"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Health Status"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "therapeutic use"
      ],
      "DescriptorName": "Immunosuppressive Agents"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "therapeutic use"
      ],
      "DescriptorName": "Interferon-beta"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy"
      ],
      "DescriptorName": "Multiple Sclerosis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Quality of Life"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Retrospective Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Surveys and Questionnaires"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}